(R)-[1-(3-羟基苯基)乙基]氨基甲酸叔丁酯 | 266369-69-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: (R)-[1-(3-羟基苯基)乙基]氨基甲酸叔丁酯
• 英文名称: (R)-[1-(3-hydroxyphenyl)ethyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl (R)-(1-(3-hydroxyphenyl)ethyl)carbamate；tert-butyl (1R)-1-(3-hydroxyphenyl) ethylcarbamate；[(R)-1-(3-Hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester；tert-butyl N-[(1R)-1-(3-hydroxyphenyl)ethyl]carbamate
• CAS: 266369-69-1
• 化学式: C₁₃H₁₉NO₃
• 分子量: 237.299
• InChiKey: WOFCTRSNCBCJCV-SECBINFHSA-N

物化性质

• 沸点：
  387.3±25.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-[1-(3-羟基苯基)乙基]氨基甲酸叔丁酯 在 盐酸 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三乙胺 、 2-(二叔丁基膦)联苯 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 反应 24.5h， 生成 (R)-1-(3-morpholin-4-yl-phenyl)ethylamine dihydrochloride
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationship of Acrylamides as KCNQ2 Potassium Channel Openers

  摘要：

  A new class of acrylamides was synthesized, and the effects of these analogues on outward potassium current were evaluated by using two electrode voltage clamp recordings from Xenopus laevis oocytes expressing cloned mKCNQ2 channels. SAR studies indicated that the pharmacophore of the acrylamide series includes the (S) absolute configuration at the (1-phenyl)ethyl moiety and the alpha,beta-unsaturated acrylamide functionality with a free NH. This study identified (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide ((S)-1) and (S)-N-[1-(4-fluoro-3morpholin-4-yl-phenyl)-ethyl]-3-(4-fluoro-phenyl)-acrylamide ((S)-2) as KCNQ2 openers for further electrophysiological evaluations. These two acrylamides demonstrated significant activity in the cortical spreading depression model of migraine as we reported previously.

  DOI：

  10.1021/jm0305826
• 作为产物：
  描述：

  (R)-(+)-1-(3-甲氧基苯基)乙胺 在 三溴化硼 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 49.0h， 生成 (R)-[1-(3-羟基苯基)乙基]氨基甲酸叔丁酯
  参考文献：
  名称：

  [EN] RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE LA RHO KINASE ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  本文提供了一些ROCK（rho激酶或rho相关激酶）的抑制剂，这些抑制剂在特定情况下可用作药物，用于治疗亨廷顿病。

  公开号：

  WO2020264405A1

文献信息

• [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE<br/>[FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2010136755A1

  公开（公告）日：2010-12-02

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O ); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  该发明提供了式（1）的化合物或其盐或互变异构体；其中X1为N或N+（O-）；X2为N或CH；Q为C1-3烷基基团；R1从氢、C1-4烃基和羟基-C2-4烃基中选择；R2、R3和R4相同或不同，每个从氢、氟、氯和甲基中选择；Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环，或者是一个萘环；Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增殖性疾病。
• Compounds with medicinal effects due to interaction with the glucocorticoid receptor
  申请人：Hamilton Morton Niall

  公开号：US20070149577A1

  公开（公告）日：2007-06-28

  The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R 1 is hydrogen, halogen, CN or (1C-4C)alkyl; R 2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R 3 and R 5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R 4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R 6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R 6 is optionally halogenated (1C-4C)alkyl; each R 7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.

  该发明提供了具有以下结构的化合物，符合以下式I的结构：其中：X是碳或氮原子；Ar是苯基或杂环芳香环；R1是氢、卤素、CN或(1C-4C)烷基；R2是氢、卤素或可选氟化的(1C-3C)烷氧基；R3和R5分别是氢、可选卤代的(1C-4C)烷基、可选卤代的(1C-4C)烷氧基、可选卤代的芳基(1C-4C)烷氧基、可选卤代的(1C-4C)烯基或羟甲基；R4是氢、卤素、可选卤代的(1C-4C)烷氧基或可选卤代的芳基(1C-4C)烷氧基；R6是氢、苄基，可选用一个或多个卤素或(1C-4C)烷基取代，或R6是可选卤代的(1C-4C)烷基；每个R7独立地是氢、卤素、可选卤代的(1C-4C)烷基或可选卤代的(1C-4C)烷氧基，以及其药用合适的酸盐，用作糖皮质激素受体调节剂，特别用于治疗中枢神经系统疾病。
• [EN] RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA RHO KINASE ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：CHDI FOUNDATION INC

  公开号：WO2020264405A1

  公开（公告）日：2020-12-30

  Provided herein are certain inhibitors of ROCK (rho-kinases or rho-associated kinases), which are useful as medicament, for the treatment Huntington's disease in particular.

  本文提供了一些ROCK（rho激酶或rho相关激酶）的抑制剂，这些抑制剂在特定情况下可用作药物，用于治疗亨廷顿病。
• Compounds for the treatment of inflammatory disorders
  申请人：Siddiqui Arshad M.

  公开号：US20060178366A1

  公开（公告）日：2006-08-10

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及式（I）的化合物：或其药学上可接受的盐、溶剂或异构体，可用于治疗由MMPs、aggrecanase、ADMP、LpxC、ADAMs、TACE、TNF-α或其组合介导的疾病或病况。
• Aromatic amine derivatives, their production and use
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07160887B1

  公开（公告）日：2007-01-09

  Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; R1 represents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; R2 represents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents —CO—, —CON(Ra)—, COO—, N(Ra)CON(Rb)—, —N(Ra)COO—, —N(Ra)SO2—, N(Ra)—, —O—, —S—, —SO— or —SO2— (in which Ra and Rb each independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from; (i) a C1-6 alkyl group, (ii) a halogeno-C1-6 alkyl group, (iii) a phenyl group, (iv) a benzyl group, (v) an optionally-substituted amino group, (vi) an optionally-substituted hydroxy group, and (vii) a carbamoyl or thiocarbamoyl group optionally substituted by: <1> a C1-6 alkyl group, <2> an optionally-substituted phenyl group, or <3> an optionally-substituted heterocyclic group, and optionally interrupted by —O— or —S—; X represents an oxygen atom, an optionally-oxidized sulfur atom, an optionally-substituted nitrogen atom, or an optionally-substituted divalent hydrocarbon group; Y represents two hydrogen atoms, an oxygen atom or a sulfur atom; . . . means that R2 may be bonded to the atom on Ring B to form a ring, or their salts, and a method for producing them.

  公式化合物：其中环A代表可选取代芳香环；环B代表可选取代的环烃基团；Z代表可选取代的环基团；R1代表氢原子、可选取代的烃基团、可选取代的杂环基团或酰基；R2代表可选取代的氨基团；D代表化学键或二价基团；E代表-CO-、-CON（Ra）-、COO-、N（Ra）CON（Rb）-、-N（Ra）COO-、-N（Ra）SO2-、N（Ra）-、-O-、-S-、-SO-或-SO2-（其中Ra和Rb各自独立地代表氢原子或可选取代的烃基团）；G代表化学键或二价基团；L代表（1）化学键或（2）二价烃基团，可选取1到5个取代基，所选取代基包括：（i）C1-6烷基，（ii）卤代C1-6烷基，（iii）苯基，（iv）苄基，（v）可选取代的氨基团，（vi）可选取代的羟基和（vii）可选取代的羰基或硫代羰基，可选取代基被- O-或-S-中断，其中： <1> C1-6烷基，<2> 可选取代的苯基或<3> 可选取代的杂环基团；X代表氧原子、可选氧化的硫原子、可选取代的氮原子或可选取代的二价烃基团；Y代表两个氢原子、一个氧原子或一个硫原子；...表示R2可以与环B上的原子结合形成环，或其盐，以及制备它们的方法。